Sep 22 2014 Published by drugmonkey under Grant Review, Grantsmanship, NIH funding
Reviewing a competing continuation of a longitudinal human subjects study always has a little bit of a whiff of extortion to it. I'm not saying this is intentional but......
The sunk cost fallacy is a monster.
3 responses so far
I have a CDA. From what I've seen and heard so far, the sunk cost fallacy could be my key to a bright and shiny future lined with R01s.
Abstract: If you don't fund this competing continuation, PATIENTS WILL DIE!!!!!!!
longitudinal in animals is qualitatively the same, just slightly less expensive.
Save my name, email, and website in this browser for the next time I comment.
DrugMonkey is an NIH-funded researcher who blogs about careerism in science. And occasionally about the science of drug use.
Site Admin | Theme by Niyaz
Drugmonkey Copyright © 2018 All Rights Reserved